KRT20: A Drug Target / Disease Biomarker (G54474)

Target Name: KRT20

NCBI ID: G54474

KRT20

KRT20: A Drug Target / Disease Biomarker

KRT20 is a protein that is expressed in the human kidney and has been identified as a potential drug target or biomarker for several diseases, including diabetes, cancer, and neurodegenerative disorders.

The kidney is a crucial organ that plays a vital role in maintaining the health and wellbeing of the body. It is responsible for removing waste products and excess fluids from the blood and maintaining a healthy balance of electrolytes and hormones. KRT20 is a key component of the kidney's filtering system, and its function is crucial for maintaining the health and function of the kidney.

KRT20 has been identified as a potential drug target due to its involvement in several key biological processes that are important for human health. One of the main functions of KRT20 is its role in regulating the movement of waste products and excess fluids out of the kidney. This is important for maintaining the health and wellbeing of the body and is a crucial function that is essential for the overall functioning of the kidneys.

In addition to its role in filtering waste products, KRT20 has also been identified as a potential drug target for its involvement in the regulation of pain perception. The kidney is involved in the production of pain hormones, and it is thought to play a key role in the regulation of pain sensitivity. KRT20 has been shown to play a role in the regulation of pain perception and may be a potential drug target for pain management treatments.

KRT20 has also been identified as a potential drug target for its involvement in the regulation of inflammation. The kidney is involved in the regulation of inflammation and is thought to play a key role in the immune response. KRT20 has been shown to play a role in the regulation of inflammation and may be a potential drug target for treatments that are designed to reduce inflammation.

In addition to its potential as a drug target, KRT20 has also been identified as a potential biomarker for several diseases, including diabetes, cancer, and neurodegenerative disorders. The kidney is a key organ that is involved in the regulation of many important biological processes, and changes in the kidney can be an indication of underlying medical conditions. KRT20 has been shown to be expressed in the urine of individuals with type 2 diabetes and has been identified as a potential biomarker for this disease.

KRT20 has also been shown to be expressed in the urine of individuals with cancer and has been identified as a potential biomarker for this disease. This suggests that KRT20 may be a useful tool for the detection and diagnosis of cancer. In addition, KRT20 has also been shown to be expressed in the urine of individuals with neurodegenerative disorders and has been identified as a potential biomarker for this disease. This suggests that KRT20 may be a useful tool for the detection and diagnosis of neurodegenerative disorders.

In conclusion, KRT20 is a protein that is expressed in the human kidney and has been identified as a potential drug target or biomarker for several diseases, including diabetes, cancer, and neurodegenerative disorders. Further research is needed to fully understand the role of KRT20 in these diseases and to develop effective treatments.

Protein Name: Keratin 20

Functions: Plays a significant role in maintaining keratin filament organization in intestinal epithelia. When phosphorylated, plays a role in the secretion of mucin in the small intestine (By similarity)

The "KRT20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRT20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets